secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001213900-25-000953
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology retains Jefferies to explore strategic alternatives including sale or licensing
--------------------------------------------------------------------------------

- Jefferies LLC appointed as exclusive financial advisor to assist in evaluating strategic alternatives.
- Alternatives under consideration include partnerships, joint ventures, mergers, acquisitions, and licensing.
- Company is preparing to launch LYMPHIR, FDA-approved for relapsed/refractory Stage I-III cutaneous T-cell lymphoma.
- No timeline set; no assurance that a transaction will result from the review process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025000953/0001213900-25-000953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025000953/ea0226665-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-000953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer